249420 — Il Dong Pharmaceutical Co Income Statement
0.000.00%
- KR₩386bn
- KR₩535bn
- KR₩601bn
Annual income statement for Il Dong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 517,468 | 561,845 | 560,132 | 637,714 | 600,758 |
Cost of Revenue | |||||
Gross Profit | 232,356 | 238,414 | 219,439 | 236,343 | 213,846 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 535,811 | 563,140 | 616,701 | 729,469 | 657,662 |
Operating Profit | -18,344 | -1,295 | -56,569 | -91,754 | -56,904 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22,634 | -9,724 | -141,205 | -119,823 | -94,273 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13,444 | -13,019 | -100,968 | -142,170 | -80,961 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -13,444 | -13,019 | -99,705 | -141,585 | -78,928 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -13,444 | -13,019 | -99,705 | -141,585 | -78,928 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -153 | -386 | -4,161 | -4,917 | -2,876 |
Dividends per Share |